The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis
NCT ID: NCT06697821
Last Updated: 2024-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
480 participants
OBSERVATIONAL
2020-05-01
2024-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Gastric Mesentery With Lymph Node Metastasis on Prognosis in Gastric Cancer Patients
NCT07139418
Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
NCT06736847
Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
NCT06728878
Effectiveness of Managing Suspected Metastasis and Progress Using Plasma D-dimer Testing in Gastric Cancer Patients
NCT04953585
Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer
NCT06405009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D2＋CME
Whether to perform the whole mesogastric excision
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. primary gastric adenocarcinoma confirmed by preoperative pathology
3. routine blood tests, liver and kidney functions and who health status score are within the range of tolerable surgery
4. it is expected to perform radical gastrectomy through d2+cme
Exclusion Criteria
2. severe mental disorder or language communication disorder
3. preoperative imaging examination or intraoperative exploration found that the patient had the following conditions: tumor involving surrounding organs requiring combined organ resection, distant organ metastasis or R0 resection could not be achieved
4. those who are not suitable for laparoscopic surgery (such as extensive adhesion caused by anterior abdominal surgery and pneumoperitoneum for various reasons).
5. concurrent malignancies at other sites
6. emergency surgery patients
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jichao Qin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jichao Qin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jichao Qin, M.D./Ph.D
Role: PRINCIPAL_INVESTIGATOR
Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJ-IRB202403050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.